).
| INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a fatal neoplasm with poor prognosis. 1, 2 Despite developments in detection and management, only approximately 8% of PDAC patients survive for 5 years after diagnosis. [3] [4] [5] Surgery is the only curative treatment for PDAC;
however, only 20% of cases are considered resectable at the time of detection. 6 Furthermore, 20% of resectable PDAC develop local recurrence and 70% develop distant recurrence after surgery. 7 With regard to recurrence, PDAC cells spread to both the surrounding tissue and distant organs in the early phase after carcinogenesis; thus, multidisciplinary therapy (surgery plus adjuvant chemotherapy) is highly recommended for all PDAC patients to manage the tumor cells that possess invasion/migration ability. Multidisciplinary therapy improves the overall survival of patients with resectable PDAC; nevertheless, the 5-year survival rate of 44.1% is not satisfactory. Taken together, approximately 95% of patients with PDAC show distant metastasis during their clinical course, and the present therapies do not sufficiently control cancer cells that possess invasion/migration ability. 8 Thus, new therapeutic targets are urgently needed to overcome metastasis in PDAC.
Epithelial-mesenchymal transition (EMT) is the differentiation process through which epithelial cells are converted into mesenchymal-like cells. Recently, numerous differences have been observed between epithelial cells and mesenchymal cells, and it was discovered that the EMT causes cells to lose their junction and apical-basal polarity, reorganize their cystoskeleton, undergo changes in the signaling programs that define their shape, and reprogram their gene expression. As a consequence of these changes, the cells show increased motility and invasion ability. 9 Numerous studies have suggested that the EMT is pivotal for the invasion and metastasis of carcinoma. [10] [11] [12] The changes in the EMT were observed in cancer cells and were induced in vitro. In the experiments, the changes in the EMT-induced cells were not permanent, which suggested the possibility that the EMT is induced by a certain epigenetic mechanism and not by a genetic change.
Histones have numerous modifications, including (but not limited to) acetylation, methylation, phosphorylation, poly-ADP ribosylation, ubiquitination, sumoylation and carbonylation. 13 With regard to histone modifications, lysine acetylation depends on the antagonistic activity of 2 enzyme classes: histone acetylases (HAT) and histone deacetylases (HDAC). 14 We previously revealed that HDAC1, one of the enzymes controlling epigenetic mechanisms, was associated with the EMT in biliary tract cancer. 15 However, there is no critical consensus on the association between the EMT and HDAC1, or in the role of HDAC1 in the multidisciplinary treatment of PDAC.
Therefore, we aimed to investigate the role of HDAC1 in distant metastasis of PDAC. We found that the expression of HDAC1 was positively associated with distant metastasis in patients with resectable PDAC. These findings were validated using PDAC cells. Furthermore, we investigated the effect HDAC inhibitors on metastasis to establish a new approach for treating PDAC with metastasis. 16 We also used radio-resistant cell clones established from Panc1 and MiaPaCa2 cells by fractionated irradiation and named them Panc1-RR and MiaPaCa2-RR cells, respectively, as reported previously. 17 In the experiment with the histone deacetylase inhibitor, Vorinostat (Selleckchem, Houston, Texas, USA) and 4-
(Santa Cruz Biotechnology, Dallas, TX, USA), PSN1 and MiaPaCa2
were treated with/without 500 nmol/L Vorinostat and with/without 5 μmol/L DHOB for 72 hours after ascertaining that the concentration had no significant effect on the viability ( Supplementary Figure S1 ).
| The downregulation of SNAIL gene
For siRNA suppression, we used a Silencer Select kit (Ambion, Austin, Texas, USA) with double-stranded RNA duplexes that targeted human SNAIL and negative control siRNA (NC), as previously described. 18 PSN was transfected with the siRNA in lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's protocol. Resected PDAC specimens were immediately fixed in 10% formalin for 48 hours. Specimens were then embedded in paraffin and sectioned into 3.5-μm slices for further evaluations, as described previously. 19 A proportion of the slides were routinely stained with H&E for pathological evaluation by a certified pathologists in our institution. The remaining slides were examined by immunohistochemistry (described below). The use of resected samples was approved by the SHINKE ET AL.
| Clinical samples
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Human Ethics Review Committee of the Graduate School of Medicine, Osaka University (17277), and informed consent was obtained from each of the patients.
| Preoperative therapy (chemoradiotherapy)
During these observation periods, 2 sequential clinical studies were recommended for PDAC patients who were eligible, as previously reported. 20 In the first trial, patients were treated with GEM (800 mg/m 2 ) and 40 Gy radiation; patients with both advanced and resectable PDAC were recommended to enroll in the study. 21 Those in the subsequent clinical trial were treated with GEM (600-1000 mg/m 2 ), S-1 (40-80 mg/m 2 ) and 50.4 Gy radiation; all patients with resectable PDAC were recommended to enroll in the study. 22 All of these patients provided their written informed consent for participation. The patients were hospitalized for 1-2 months when receiving chemoradiotherapy to observe the safety of the therapy.
| Immunohistochemistry
Immunohistochemical studies of HDAC1 and SNAIL were performed on 103 surgical specimens of PDAC, as described previously. 18, 23 Briefly, formalin-fixed, paraffin-embedded tissues were deparaf- 
| Western blotting
Western blotting was performed as described previously. 24 
| Quantitative RT-PCR
The quantitative RT-PCR (qRT-PCR) was performed as previously described. 15 Briefly, total RNA was isolated from cell lines with TRIzol Reagent (Invitrogen). For the mRNA evaluations, complementary DNA was synthesized with the Reverse Transcription System (Promega, Tokyo, Japan). Then, a qRT-PCR was performed with specifically-designed oligonucleotide primers (Supplementary Table S2 ) and a LightCycler 480 Real-Time PCR system (Roche Diagnostics, Mannheim, Germany). The amplification products were quantified with the LightCycler-DNA master SYBR Green I Kit (Roche Diagnostics).
The target gene expression levels were normalized to the β-actin expression level, which served as an endogenous control.
| Immunocytochemical staining
Immunocytochemistry (ICC) was performed as described previously. 15 Briefly, cells were fixed with 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100, and blocked with 1% BSA for 10 minutes at room temperature.
Subsequently, the cells were stained with the following antibodies: 
| Growth inhibition assays and the determination of cell viability with GEM therapy
Growth inhibition was assessed using the MTT assay (Sigma-Aldrich Co, St. Louis, MO, USA) as described previously. 25 Each cell line was seeded onto a 96-well plate (5 × 10 3 cells/well) and incubated for 24 hours. Subsequently, the cells were exposed to GEM, Vorinostat or DHOB (at several concentrations) for 72 hours. Cell viability was then evaluated by absorbance using MTT solution. The results were expressed as the percentage of absorbance relative to that of untreated controls.
| The histone deacetylases activity assay
Nuclear proteins were extracted with a Nuclear Extract Kit (Abcam).
The HDAC1 activity was subsequently measured with an HDAC Activity Assay Kit (Epigentek, Farmingdale, NY, USA). All procedures were conducted according to the manufacturer's recommendations.
| Invasion assays
The invasion assay was performed with invasion chambers loaded Table S3 ).
The univariate analysis of factors associated with PFS (Table 1) revealed several clinicopathological features that were significantly associated with PFS: the serum CEA level (P < 0.0001), the presence of jaundice (P = 0.0185), completion of adjuvant therapy The multivariate analysis of these risk factors revealed that the HDAC1 expression (as determined by IHC) was an independent prognostic factor (P = 0.0207), as were the CEA level (P < 0.0001), the presence of jaundice (P = 0.0091) and the completion of adjuvant therapy (P = 0.0146).
To determine the type of relapse that was most related to the expression of HDAC1, distant metastasis-free survival (DMFS) and local progression-free survival (LPFS) were evaluated. The DMFS in the HDAC1 high group was significantly shorter than that in the HDA-C1 low group (P = 0.0123), whereas there was no significant difference in the LPFS of the 2 groups (P = 0.1348, Figure 1C ). Taken together, these findings suggest that a large number of HDAC1-positive PDAC cells indicated the presence of occult distant metastasis.
Thus, it was suggested that HDAC1 induced the migration/invasion ability in PDAC cells. Furthermore, chemotherapy and radiotherapy did not seem to affect the HDAC1 expression because preoperative therapy did not change the ratio of the HDAC1 expression.
To understand the influence of HDAC expression on the sensi- 
F I G U R E 2
The HDAC1 activity and the epithelial-mesenchymal transition (EMT) in the PDAC cell lines, PSN1, MiaPaCa2, Panc1 and BxPC3. The mean ± standard deviation (SD) is depicted. Significant differences were observed between the values under the horizontal lines (*P < 0.05, **P < 0.01). HDAC1 activities (A) and the mRNA expression of HDAC1 (B) in each PDAC cell line. C, The fold change of the number of invasive cells in each PDAC cell line is depicted. The number of BxPC3 cells was set as the control. D, The mRNA expression of the EMT-related genes in each PDAC cell line is depicted; Cytokeratin 19 (as an epithelial marker), Vimentin (as a mesenchymal marker), SNAIL, ZEB1 and SLUG (as EMT-related transcriptional factors). Neither ZEB2 nor TWIST were detected in these PDAC cell lines. E, The protein expression in each PDAC cell line was determined by western blotting. The expression level of each protein was normalized by dividing with the corresponding housekeeping protein expression and is depicted below. The expression of HDAC1 in the extracted nuclear proteins is shown in the upper panels. The expression of CK19 in whole cell lysate proteins is shown in the lower panels. In the extracted nuclear proteins, the expression of HDAC1 was highest in PSN1 rather than other PDAC cell lines. In whole cell lysates, the CK19 expression in BxPC3 was highest in 4 PDAC cell lines. F, Immunocytochemistry to detect the expression of HDAC1 and CK 19 in PDAC cells. HDAC1 and CK 19 were stained red or green, respectively. The nuclei stained with Hoechst appear blue. Scale bar: 100 μm. In PSN1 and MiaPaCa2, HDAC1 was highly expressed and CK19 was slightly expressed; these cells had a spindle-like shape. In Panc1 and BxPC3, the HDAC1 expression was low and the CK19 expression was high; these cells had a valvate-like shape Previous studies reported that the EMT is pivotal for metastasis in PDAC. 27, 28 In the present study, we demonstrated that the expression of HDAC1 was associated with metastasis in PDAC through the EMT. Von Burstin et al 28 Our study demonstrated that HDAC1 inhibitors only target the migration ability; thus, it must be added to the present standard therapies. However, there are no reports on the HDAC activity in PDAC in patients undergoing chemotherapy or radiotherapy. In the present study, we investigated specimens from patients who had been treated with/without preoperative therapy, and found no difference in their expression of HDAC1 (Supplementary Table S3 ). This led us to hypothesize that HDAC1 inhibitor treatment would work well regardless of the influence of chemotherapy or radiotherapy. Thus, we assumed that unresectable local advanced PDAC could be a suitable target for HDAC inhibitor treatment (as part of a multidisciplinary approach). There are some reports about the evaluation of the HDAC1 expression in clinical samples. [30] [31] [32] These reports also suggest that HDAC1 could be a therapeutic target in patients with PDAC. 28, 29 However, there is no consensus as to which patients should be treated by HDAC inhibitors in the clinical setting. This is the first study to investigate the possibility of applying HDAC inhibitor treatment for PDAC in the clinical setting.
We reported that the HDAC1 inhibitor suppressed invasiveness, and that SNAIL seemed to play a dominant role in this mechanism. An epigenetic enzyme of HDAC1 could regulate other genes related to invasiveness, and several studies have reported that an epigenetic mechanism governs SNAIL to induce the EMT. 33 SNAIL is one of the SNAG domains, which contain zinc finger proteins, and a number of SNAG-associated histone modification complexes (ie, Sin3A-HDAC1/2, EZH2/-HDAC1/2, LSD1-CoREST and Ajuba-PRMT5) have been identified. [34] [35] [36] [37] [38] The manner in which the complexes are orchestrated and assembled at the target chromatin has been reported. 33 Peinado et al 38 state that Snail mediates E-cadherin through the recruitment of the Sin3A/HDAC1/HDAC2 complex in MDCK cells and MCA3D cells. Von
Burstin et al 28 report that Snail/HDAC1/HDAC2 repressor complex in PDAC suppresses the EMT regulating metastasis. Although these studies all referred to the regulation of metastasis, our results were not contradictory to them. Moreover, we assumed that a pan-HDAC inhibitor is more effective to this mechanism than an HDAC1-selective inhibitor because it induces downregulations of both HDAC1 and HDAC2.
In our study, we treated cells with Vorinostat, which is a pan-HDAC inhibitor, and DHOB, which is a HDAC1-selective inhibitor.
Although the results would be much more convincing with a HDAC1 knockdown experiment, PDAC cells unfortunately lost viability with F I G U R E 3 Treatment of PDAC cells with Vorinostat. The mean ± standard deviation (SD) is shown. Significant differences were observed between the values under the horizontal lines (*P < 0.05, **P < 0.01). A, The alternation of HDAC1 activity in PSN1 or in MiaPaCa2 with Vorinostat treatment. HDAC1 activity in both PSN1 and MiaPaCa2 was significantly inhibited for 72 h. B, The alternation in the number of invasive cells with Vorinostat treatment. The percentage of the initial change after treatment is shown. Invasiveness in PSN1 and MiaPaCa2 decreased with Vorinostat treatment. C, The alternation of the EMT-related genes with/without Vorinostat treatment in PSN1 and MiaPaCa2. The mRNA expression of CK19 in both PSN1 and MiaPaCa2 was significantly increased by Vorinostat treatment, and the expression of Vimentin in both PSN1 and MiaPaCa2 was significantly decreased. The mRNA expression of SNAIL in PSN1 and MiaPaCa2 was significantly decreased by Vorinostat treatment. The mRNA expression of ZEB1 in MiaPaCa2 was significantly decreased by Vorinostat treatment. D, The protein expression in PSN1 and MiaPaCa2 with/without Vorinostat treatment, as determined by western blotting. The expression of ZEB1 and SNAIL in the extracted nuclear proteins is shown in the upper panels. The expression of CK19 in whole cell lysate proteins was used for the expression levels in the lower panels. In the extracted nuclear proteins, the expression of SNAIL in PSN1 and MiaPaCa2 was decreased by Vorinostat treatment. In whole cell lysates, the CK19 expression in PSN1 and MiaPaCa2 was increased by Vorinostat treatment. E, Immunocytochemistry to detect the expression of HDAC1 and CK 19 in PDAC cells with/without Vorinostat treatment. HDAC1 and CK19 were stained red and green, respectively. The Hoechst-stained nuclei appear blue. Scale bar: 100 μm. The CK19 expression in PSN1 and MiaPaCa2 was increased by Vorinostat treatment HDAC1 knockdown, and, thus, we did not use HDAC1 knockdown cells in our study.
In conclusion, we demonstrated that the HDAC1 expression in PDAC indicated greater migration ability, and that the expression was not influenced by chemotherapy or radiotherapy. The results of the present study suggest that therapy targeting HDAC1 is a promising treatment option for PDAC, and that it would suppress metastasis by inhibiting the EMT.
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